Epirubicin versus doxorubicin: Which is the anthracycline of choice for the treatment of breast cancer?

Clinical Breast Cancer

Volumn 4, Issue SUPPL. 1, 2003, Pages

  Kaklamani, Virginia G ^a   Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adjuvant chemotherapy; Combination chemotherapy; Micrometastatic disease; Surgical resection

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; CELECOXIB; CYCLOPHOSPHAMIDE; DEFEROXAMINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IRON CHELATING AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; PACLITAXEL; PREDNISOLONE; TAMOXIFEN; TRASTUZUMAB;

ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; FEMALE; GENDER; HUMAN; LEUKEMIA; LEUKOPENIA; NAUSEA AND VOMITING; PREVALENCE; REVIEW; STOMATITIS;

EID: 0038783150     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2003.s.012     Document Type: Review

References (44)

1. Jemal A, Murray T, Samuels A, et al. Cancer Statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352:930-942.
3. Findlay BP, Walker-Dilks C. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1998; 2:140-146.
4. Mouridsen HT, Alfthan C, Bastholt L, et al. Current status of epirubicin (Farmorubicin) in the treatment of solid tumours. Acta Oncol 1990; 29:257-285.
5. Herait P, Poutignat N, Marty M, et al. Early assessment of a new anti-cancer drug analogue - are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer 1992; 28A:1670-1676.
6. Myers C, Gianni L, Zweier J, et al. Role of iron in adriamycin biochemistry. Fed Proc 1986; 45:2792-2797.
7. Hershko C, Link G, Tzahor M, et al. Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture. J Lab Clin Med 1993; 122:245-251.
8. Link G, Tirosh R, Pinson A, et al. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 1996; 127:272-278.
9. Jain MK, Jahagirdar DV, Van Linde M, et al. Solute-induced acceleration of transbilayer movement and its implications on models of blood-brain barrier. Biochim Biophys Acta 1985; 818:356-364.
10. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19:3817-3827.
11. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. J Clin Oncol 1988; 6:679-688.
12. Phase III randomized study of fluorouracil, epirubicin, and cyclophoshamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. J Clin Oncol 1988; 6:976-982.
13. Lopez M, Papaldo P, Di Lauro L, et al. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. Oncology 1989; 46:1-5.
14. Heidemann E, Steinke B, Hartlapp J, et al, Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. Onkologie 1990; 13:24-27.
15. Lawton PA, Spittle MF, Ostrowski MJ, et al. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma. Clin Oncol (R Coll Radiol) 1993; 5:80-84.
16. Gasparini G, Dal Fior S, Panizzoni GA, et al. Weekly epirubicin versus doxorabicin as second line therapy in advanced breast cancer: a randomized clinical trial. Am J Clin Oncol 1991; 14:38-44.
17. Castiglione M, Schtzmann E, Goldhirsch G. Adriamycin vs. epirubicin: low dose weekly schedule in metastatic breast cancer. Preliminary results of tumor response and of quality of life measurements. Proc Am Soc Clin Oncol 1990; 9:48 (Abstract #182).
18. Hortobagyi GN, Yap HY, Kau SW, et al. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol 1989; 12:57-62.
19. Focan C, Andrien JM, Closon MT, et al. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. J Clin Oncol 1993; 11:1253-1263.
20. Habeshaw T, Paul J, Jones R, et al. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. J Clin Oncol 1991; 9:295-304.
21. Bastholt L, Dalmark M, Gjedde SB, et al. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996; 14:1146-1155.
22. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 1993; 19:197-228.
23. Von Hoff DD, Layard MW, Bass P, et al, Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91:710-717.
24. Praga C, Beretta G, Vigo PL, et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63:827-834.
25. Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol 1998; 16:3502-3508.
26. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8:1482-1496.
27. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000; 92:1991-1998.
28. Andersson M, Madsen EL, Overgaard M, et al. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer - a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1999; 3:39-46.
29. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16:2651-2658.
30. Levine MN, Pritchard KI, Bramwell VHC, et al. A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA.5. Breast Cancer Res Treat 2002; 76:S33 (Abstract #17).
31. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001; 19:602-611.
32. Bonneterre JM, Roche H, Kerbrat P, et al. Long-Term cardiac follow-up in free of disease patients after receiving 6 FEC-60 vs 6 FEC-100 (FASG-05) as adjuvant chemotherapy for node-positive (N+) breast cancer. Proc, Am Soc Clin Oncol 2002; 21:39a (Abstract #154).
33. Mouridsen H, Andersen J, Andersson M, et al. Adjuvant anthracycline in breast cancer. improvemed outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc Am Soc Clin Oncol 1999;18:68a (Abstract #254).
34. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 30:1253-1259.
35. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330:1260-1266.
36. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 2:976-983.
37. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
38. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737-744.
39. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648.
40. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994; 9:1829-1838.
41. Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998; 17:2235-2249.
42. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241-2251.
43. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
44. Eidtmann H, Thomssen C, Untch M, et al. Herceptin in combination with epirubicin plus cyclophosphamide: cardiac safety and efficacy in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21:60a (Abstract #236).